Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lifecare AS ( (DE:LFC0) ) just unveiled an announcement.
Lifecare ASA has received a preliminary assessment from the Norwegian Medical Products Agency (NoMA) for its application to conduct a first-in-human clinical study of its proprietary CGM system. The assessment is a routine part of the regulatory process, and NoMA has requested additional procedural and technical information, pausing the review timeline. Lifecare is preparing the necessary documentation and expects to submit it soon. The pilot study, which will be conducted at the University of Bergen, is crucial for the company’s CE-marking trial and European market launch planned for 2027.
More about Lifecare AS
Lifecare ASA is a MedTech company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company specializes in medical sensor technology that enables the monitoring of various body analytes using osmotic pressure as a sensing principle.
Average Trading Volume: 102,059
Current Market Cap: NOK105.6M
See more insights into LFC0 stock on TipRanks’ Stock Analysis page.